Sana Biotechnology Inc
SANAHealthcare|Biotechnology|USA
$3.85
-0.08 (-2.04%)
About
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Stock Price
-5.3%(1Y)
Pipeline Summary
48 total trials5
Phase 1
5
Phase 2
0
Phase 3
1
Phase 4
Recruiting: 8Completed: 26Active: 3Unknown: 6Terminated: 1Withdrawn: 2NOT_YET_RECRUITING: 2
Active Trials (11)
The Myelin Disorders Biorepository Project
NCT03047369Leukodystrophy
Recruiting
Enrollment: 12,000 participants
To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital
NCT07337434Chronic Plaque Psoriasis
Early P1Recruiting
Enrollment: 106 participants
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
NCT05878184Non Hodgkin Lymphoma
Phase 1Active
Enrollment: 16 participants
First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes
NCT06239636Type1diabetes
Early P1Recruiting
Enrollment: 2 participants
Postoperative Cryocuff vs. Conventional Icepack in TKA - What is More Effective in Reducing Pain and Swelling?
NCT07627854Postoperative Swelling After TKA
N/ARecruiting
Enrollment: 102 participants
BioScore
2.9/10
High Risk
Ownership
Recent Insider Trades
FMR LLCSELL
2025-01-08290,912 shares @ $6.49
Mulligan RichardSELL
2024-09-25300,000 shares @ $3.99
Yang Patrick YSELL
2024-03-0825,000 shares @ $9.45
CRANDELL KEITHBUY
2024-02-081,818,181 shares @ $5.5
ARCH Venture Fund X Overage, L.P.BUY
2024-02-081,818,181 shares @ $5.5
Data last updated: Jul 13, 2026, 12:47 PM